BioXcel Therapeutics, Inc. Payments of Stock Issuance Costs
BioXcel Therapeutics, Inc. (BTAI) reported Payments of Stock Issuance Costs of $220.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-13
- BioXcel Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $62.00K, a 1966.67% increase year-over-year.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $158.00K, a 80.32% decline year-over-year.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $115.00K, a 35.75% decline year-over-year.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $686.00K, a 4800.00% increase year-over-year.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $1.61M, a 239.03% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for fiscal 2024 was $474.00K, a 41.55% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $811.00K.
- BioXcel Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $3.54M, a 80.12% decline from fiscal 2020.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 1 month as first filed | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $220.00K 10-Q · filed 2026-08-13 | $335.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.02M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $158.00K 10-Q · filed 2026-05-15 | $273.00K derived: sum of 2 quarters · filed 2026-05-15 | $959.00K derived: sum of 3 quarters · filed 2026-05-15 | $962.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $801.00K derived: sum of 2 quarters · filed 2026-03-27 | $804.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.61M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $689.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.49M 10-Q · filed 2025-11-12 | $1.67M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $806.00K 10-Q · filed 2026-08-13 | $985.00K derived: sum of 3 quarters · filed 2026-08-13 | $999.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $803.00K 10-Q · filed 2026-05-15 | $982.00K derived: sum of 2 quarters · filed 2026-05-15 | $996.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.16M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $193.00K derived: sum of 2 quarters · filed 2026-03-27 | $357.00K derived: sum of 3 quarters · filed 2026-03-27 | $474.00K 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $178.00K derived: sum of 2 quarters · filed 2025-11-12 | $295.00K 10-Q · filed 2025-11-12 | $367.00K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $281.00K 10-Q · filed 2025-08-12 | $353.00K derived: sum of 3 quarters · filed 2025-08-12 | $353.00K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $117.00K 10-Q · filed 2025-05-12 | $189.00K derived: sum of 2 quarters · filed 2025-05-12 | $189.00K derived: sum of 3 quarters · filed 2025-05-12 | $189.00K derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $72.00K derived: sum of 2 quarters · filed 2025-03-28 | $72.00K derived: sum of 3 quarters · filed 2025-03-28 | $811.00K 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $739.00K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $739.00K 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | $739.00K 10-Q · filed 2024-05-09 | ||||||
| 2021-12-31 | $3.54M 10-K · filed 2023-03-16 | ||||||
| 2021-06-30 | $3.04M 10-K · filed 2023-03-16 | $3.54M 10-Q · filed 2022-11-14 | |||||
| 2020-12-31 | $17.82M 10-K · filed 2022-03-11 | ||||||
| 2020-09-30 | $12.99M 10-Q · filed 2021-11-10 | ||||||
| 2020-07-31 | $13.03M 10-K · filed 2022-03-11 | $12.99M 10-Q · filed 2020-11-12 | |||||
| 2020-03-31 | $4.79M 10-Q · filed 2021-11-10 | ||||||
| 2020-02-29 | $4.79M 10-K · filed 2022-03-11 | ||||||
| 2019-12-31 | $1.99M 10-K · filed 2021-03-12 | ||||||
| 2019-09-30 | $1.58M 10-K · filed 2021-03-12 | $1.99M 10-Q · filed 2020-11-12 | $2.00M derived: sum of 2 quarters · filed 2020-11-12 | $7.90M derived: sum of 3 quarters · filed 2020-11-12 | |||
| 2019-09-26 | $1.58M 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | $11.00K 10-Q · filed 2020-11-12 | $378.00K 10-Q · filed 2020-08-14 | |||||
| 2019-03-31 | $5.90M 10-Q · filed 2019-05-07 | ||||||
| 2018-12-31 | $5.90M 10-K · filed 2020-03-09 | ||||||
| 2018-03-31 | $1.24M 10-Q · filed 2018-11-09 | $5.90M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |